ImmunoPrecise Antibodies launches vaccine development program for COVID-19

ImmunoPrecise Antibodies has launched a coronavirus vaccine development program to address the new coronavirus originating in Wuhan, China apart from developing coronavirus-neutralizing antibodies for addressing prophylactic and therapeutic measures to counter the virus and its associated disease, COVID-19.

So far, COVID-19 has claimed the lives of nearly 1,875 people, while infecting more than 74,000 across the world.

ImmunoPrecise Antibodies said that it has designated Dr. Ilse Roodink, the chairwoman of its subsidiary Talem Therapeutic’s scientific committee, as the Coronavirus Global Project Leader. Under her supervision, the Canadian pharma company has taken up a global response and properly designed campaign.

ImmunoPrecise Antibodies claims that its sophisticated infrastructure considerably contributed to a quick, yet sensible, response launched by the design and production of relevant SARS-CoV-2 target antigens. This, the company says will enable in the upcoming identification of prophylactic and therapeutic compounds using its discovery platforms such as B Cell Select and DeepDisplay and also the access of Talem Therapeutic to the transgenic animal platform OmniAb for direct generation of human antibodies.

Dr. Jennifer Bath – President and CEO of ImmunoPrecise Antibodies said: “We believe that ImmunoPrecise will make an impressive contribution to the global fight against SARS-CoV-2. With the aid of iterative advancements rapidly compiling from across the globe, including data such as the February 19th release of the prefusion form of the new coronavirus spike glycoprotein, research teams are advancing the collective effort toward the development of efficacious vaccines, therapeutic antibodies, and diagnostics.

“We grow more determined each day about contributing to this endeavor, as we monitor the rapid, global spread of SARS-CoV-2.”

Know more about Coronavirus symptoms in humans here.